Sugi Predict

Sugi Predict / Compounds / SCHEMBL1398690

SCHEMBL1398690

SCHEMBL1398690

CC(C)(C)OC(=O)N1CC[C@H]1CN

nearest known ligand 0.46

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ PDE8B O95263 1/20 0.39
▸ ATM Q13315 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ CTSK P43235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630474 1.00 HTT (0.43) HTTHSD17B10CHRM2CHRM1CHRM3
SCHEMBL1630475 1.00 HTT (0.43) HTTHSD17B10CHRM2CHRM1CHRM3
SCHEMBL337037 0.90 HSD17B10 (0.48) HSD17B10PDE8BATMSMN1; SMN2
SCHEMBL337349 0.90 HSD17B10 (0.48) HSD17B10PDE8BATMSMN1; SMN2
SCHEMBL205359 0.90 HSD17B10 (0.48) HSD17B10PDE8BATMSMN1; SMN2
Hydrochloric Acid SCHEMBL1026857 0.89 HSD17B10 (0.47) HSD17B10PDE8BATMSMN1; SMN2
Hydrochloric Acid SCHEMBL1027414 0.89 HSD17B10 (0.47) HSD17B10PDE8BATMSMN1; SMN2
SCHEMBL80021 0.89 PDE8B (0.49) HSD17B10HPGDPDE8BATMSMN1; SMN2
SCHEMBL283705 0.89 PDE8B (0.49) HSD17B10HPGDPDE8BATMSMN1; SMN2
SCHEMBL344947 0.89 PDE8B (0.49) HSD17B10HPGDPDE8BATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
US-20260008778-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-12492181-B2 Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2025-12-09 — — US disclosed
US-12391686-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-19 — — US disclosed
US-20250250230-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-08-07 — — US disclosed
US-20250197402-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-06-19 — — US disclosed
EP-4508027-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-02-19 — — EP disclosed
CN-113149983-B Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2024-03-29 — — CN disclosed
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 — — US disclosed
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 — — US disclosed
EP-2069332-B1 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2011-03-02 — — EP disclosed
US-20100331294-A1 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-12-30 — — US disclosed
US-20100331294-A1 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-12-30 — — US disclosed
US-20100331294-A1 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-12-30 — — US disclosed
US-20100222600-A1 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 — — US disclosed
US-20100152450-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF PSYCHOGENICS, INC. (US) 2010-06-17 — — US disclosed
US-20100152450-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF PSYCHOGENICS, INC. (US) 2010-06-17 — — US disclosed
CN-101506199-A Azetidine compounds as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD (CH) 2009-08-12 — — CN disclosed
EP-2069332-A2 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-06-17 — — EP disclosed
WO-2008020405-A2 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250230-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R HTT 570/4885HSD17B10 1513/4885CHRM2 381/4885
US-20100222600-A1 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R HTT 473/4885HSD17B10 4066/4885CHRM2 206/4885
US-12391686-B2 Compounds and uses thereof VHL, TFEB, BECN1 HTT 377/4885HSD17B10 2878/4885CHRM2 4880/4885
US-20100152450-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF CHRNG, CHRNA5, CHRNA2 HTT 1500/4885HSD17B10 2252/4885CHRM2 21/4885
US-12492181-B2 Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC1R, MC3R, MC2R HTT 973/4885HSD17B10 3728/4885CHRM2 602/4885
US-20260008778-A1 COMPOUNDS AND USES THEREOF BRD9, BCL9L, BCL9 HTT 2939/4885HSD17B10 2980/4885CHRM2 1951/4885
US-20100331294-A1 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES HRH2, HRH4, HRH3 HTT 3249/4885HSD17B10 3863/4885CHRM2 70/4885
US-20240067642-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 HTT 304/4885HSD17B10 2945/4885CHRM2 4878/4885
US-20250197402-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK HTT 2961/4885HSD17B10 4087/4885CHRM2 4799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.